Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence

article published in the Proceedings of the National Academy of Sciences of the United States of America

Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1073/PNAS.1805267115
P932PMC publication ID6065014
P698PubMed publication ID29987026

P50authorBeatrice H. HahnQ55293537
Tanmoy BhattacharyaQ55414889
Alan S. PerelsonQ55719625
George M. ShawQ78514357
Ruy M. RibeiroQ30504775
P2093author name stringHui Li
Elena E Giorgi
Shuyi Wang
Ruian Ke
Richard J O Barnard
Wenge Ding
P2860cites workAvoiding the void: cell-to-cell spread of human virusesQ22251022
Beneficial mutation selection balance and the effect of linkage on positive selectionQ24685465
Viral quasispecies evolutionQ27013917
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replicationQ27472912
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAsQ27473092
Viral and Cellular Determinants of Hepatitis C Virus RNA Replication in Cell CultureQ27473345
Superinfection Exclusion in Cells Infected with Hepatitis C VirusQ27478378
Analysis of Hepatitis C Virus Superinfection Exclusion by Using Novel Fluorochrome Gene-Tagged Viral GenomesQ27480348
Pre-existence and emergence of drug resistance in HIV-1 infection.Q52264204
Superinfection and the evolution of parasite virulence.Q52382956
The fate of competing beneficial mutations in an asexual population.Q54262235
Antiretroviral dynamics determines HIV evolution and predicts therapy outcomeQ36374300
Mechanism-based pharmacodynamic modelingQ36933670
Vacated niches, competitive release and the community ecology of pathogen eradicationQ37037427
Global control of hepatitis C: where challenge meets opportunityQ37077112
Evasion of superinfection exclusion and elimination of primary viral RNA by an adapted strain of hepatitis C virus.Q37336829
Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liverQ37684887
Genetic recombination of the hepatitis C virus: clinical implicationsQ37828637
The role of mutational robustness in RNA virus evolutionQ38092577
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept studyQ38375284
In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistanceQ38868283
Modeling Viral SpreadQ38952060
Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cellsQ40425026
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionQ40908880
Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infectionQ41722674
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirinQ42201573
Pre-existence and emergence of drug resistance in a generalized model of intra-host viral dynamics.Q42277513
A comprehensive hepatitis C viral kinetic model explaining cureQ42997057
Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamicsQ42999813
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.Q43039341
Influence of viral replication mechanisms on within-host evolutionary dynamicsQ46082049
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapyQ27860724
Coinfection and the evolution of parasite virulenceQ28290024
A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variantsQ28473678
Elucidation of hepatitis C virus transmission and early diversification by single genome sequencingQ28482493
Evolutionary analysis of human immunodeficiency virus type 1 therapies based on conditionally replicating vectorsQ28484825
Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus InfectionQ28545971
Antibody neutralization and escape by HIV-1Q29547345
Unifying the epidemiological and evolutionary dynamics of pathogensQ29619092
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionQ29619510
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytesQ30004698
Influenza A virus uses intercellular connections to spread to neighboring cellsQ30616850
Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentrationQ30685690
Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearanceQ33631104
Low dynamic state of viral competition in a chronic avian hepadnavirus infectionQ33787127
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-lifeQ34035703
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variantsQ34276394
Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale modelQ34334375
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rateQ34395271
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): aQ34451681
Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytesQ34504820
Rapid emergence of protease inhibitor resistance in hepatitis C virusQ34551913
A perspective on modelling hepatitis C virus infectionQ34759489
Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liverQ34969032
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.Q35012057
Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virusQ35164008
Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4Q35172385
The role of cells refractory to productive infection in acute hepatitis B viral dynamicsQ35691056
Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling ApproachQ35745457
Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k/1bQ35826504
Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation SequencingQ36066888
P275copyright licenseCreative Commons Attribution-NonCommercial-NoDerivs 4.0 InternationalQ24082749
P6216copyright statuscopyrightedQ50423863
P433issue30
P407language of work or nameEnglishQ1860
P921main subjectHepatitis C virusQ708693
superinfectionQ1563808
P304page(s)E7139-E7148
P577publication date2018-07-24
P1433published inProceedings of the National Academy of Sciences of the United States of AmericaQ1146531
P1476titleSuperinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence
P478volume115

Reverse relations

cites work (P2860)
Q63762397Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants
Q64064863HCV transmission in high-risk communities in Bulgaria
Q63740385Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs
Q91867190Within-host infectious disease models accommodating cellular coinfection, with an application to influenza

Search more.